118 HR 3884 RH: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 U.S. House of Representatives 2023-08-25 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IBUnion Calendar No. 132118th CONGRESS1st SessionH. R. 3884[Report No. 118–166]IN THE HOUSE OF REPRESENTATIVESJune 7, 2023Mr. Burgess (for himself, Mr. Davis of Illinois, and Mr. Carter of Georgia) introduced the following bill; which was referred to the Committee on Energy and CommerceAugust 25, 2023Additional sponsor: Ms. Lee of CaliforniaAugust 25, 2023Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printedStrike out all after the enacting clause and insert the part printed in italicFor text of introduced bill, see copy of bill as introduced on June 7, 2023A BILLTo amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.

1.

Short title

This Act may be cited as the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023.

2.

Reauthorization of sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment

Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b–5(b)) is amended—(1)in paragraph (3)(A), by inserting , grant, or cooperative agreement after contract; and (2)in paragraph (6), by striking $4,455,000 for each of fiscal years 2019 through 2023 and inserting $8,205,000 for each of fiscal years 2024 through 2028.

August 25, 2023Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed